ADVANCED INSTRUMENTS acquired by PATRICIA INDUSTRIES
Context
Patricia Industries, backed by the industrial holding power of Investor AB, has finalized the acquisition of Advanced Instruments from Windjammer Capital. The strategic rationale for this transaction centers on a "resilience-driven" play, merging the target's undisputed leadership in the specialized osmolality testing market with the acquirer's long-term capital and healthcare sector expertise. This fusion effectively secures a high-margin, capital-light platform that benefits from non-discretionary demand across clinical and biopharmaceutical end markets. This operation allows the organization to execute a definitive structural expansion into the high-growth cell and gene therapy sectors, where the target's instrumentation is a mission-critical component of complex biologics production. By incorporating the target's innovative technology and deep customer relationships into its global industrial network, the organization can now provide more robust and integrated solutions for pharmaceutical quality control. The maneuver optimizes the group's portfolio by adding a business characterized by high recurring revenue and strong cash conversion. Ultimately, the partnership solidifies the group's standing as a primary enabler of analytical precision, bridging the gap between clinical diagnostic excellence and industrialized biopharmaceutical manufacturing standards.
ADVANCED INSTRUMENTS, which reported an EBITDA margin of [members only] in 2019, is valued in this transaction at an EV/EBITDA multiple of Above 20x, representing a premium to the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Advanced Instruments operates as a premier technology organization dedicated to the engineering and distribution of specialized analytical instrumentation for the clinical, biopharmaceutical, and food and beverage sectors. The entity’s business model is centered on a proprietary framework of osmolality testing, providing critical diagnostic and quality control solutions for complex biologics and clinical diagnostics. Its value proposition is anchored in technical operational depth, serving as the global standard for fluid particle measurement in medical and industrial settings. Strategically, the firm focuses on the high-growth biopharmaceutical market, particularly within cell and gene therapy applications, while maintaining a resilient core in hospital diagnostics. By maintaining a specialized focus on technical excellence and customer-centricity, the organization ensures a mission-critical role in the structural efficiency of laboratory workflows and pharmaceutical production. The entity prioritizes technical innovation and industrialized precision to facilitate the structural advancement of patient diagnostics and product quality standards.
Ent. Value
$500M–1.5bn
Equity Value
[members only]
Multiples
EV / Revenue
Above 6x
EV / EBITDA
Above 20x
EV / EBIT
[members only]
Historical Financials (USD)
Similar deals in Life Sciences
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 10/2020 | ARDIAN | H2 PHARMA | FRANCE | CDMO |
| 10/2020 | SULZER | HASELMEIER | SWITZERLAND | Medical Consumables |
| 09/2020 | EQT PARTNERS | SCHÜLKE | GERMANY | Medical Consumables |
| 09/2020 | PERMIRA | NEURAXPHARM | GERMANY | Generics / Labs |
| 06/2020 | AVISTA CAPITAL PARTNERS | VISION HEALTHCARE | BELGIUM | Nutrition & Dietary Supplements |
| 04/2020 | AMERICAN SECURITIES | PARAGON MEDICAL | UNITED STATES | Medical Devices |
| 04/2020 | WARBURG PINCUS | POLYPLUS | FRANCE | R&D Biotech |
| 04/2020 | ROYAL DSM | GLYCOM | DENMARK | Nutrition & Dietary Supplements |
| 03/2020 | LBO FRANCE | DUTSCHER | FRANCE | Medical Consumables |
| 02/2020 | PERRIGO COMPANY | HIGH RIDGE BRANDS (ORAL CARE PORTFOLIO) | UNITED STATES | Generics / Labs |
Other operations with PATRICIA INDUSTRIES
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 07/2025 | PATRICIA INDUSTRIES | NOVA BIOMEDICAL | UNITED STATES | Diagnostic Equipment |
REFERENCES
Valuation range: EV $500M–1.5bn
Revenue range: $50–100M
EBITDA range: $25–50M
EV/Revenue range: Above 6x
EV/EBITDA range: Above 20x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of ADVANCED INSTRUMENTS by PATRICIA INDUSTRIES are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Acquirer: patricia industries